What side effects are most commonly reported with Cinqair (reslizumab)?
Cinqair (reslizumab) is an asthma biologic given by IV infusion. The side effects most often associated with it are infusion-related reactions, including symptoms such as:
- Throat tightness
- Nausea
- Flushing
- Dizziness
- Rash
- Itching
These reactions can occur during or around the time of infusion.
What serious side effects should patients watch for?
The most important serious risk is anaphylaxis (a severe allergic reaction). Patients are advised to seek emergency care if they develop symptoms such as:
- Trouble breathing or wheezing
- Swelling of the face, lips, or throat
- Severe dizziness or fainting
- Hives or widespread rash
How might Cinqair affect lab tests or increase infection risk?
Commonly discussed adverse effects for Cinqair focus on allergic and infusion-type reactions. If you have specific lab monitoring guidance from your prescriber, follow that plan, because monitoring can vary by patient and treatment history.
What does “infusion-related reaction” mean in practice?
Because Cinqair is administered intravenously, reactions can happen during the infusion or shortly after. Clinicians typically monitor patients during and after dosing to catch allergic symptoms early.
Do side effects differ by dosing frequency or other asthma meds?
Side effects are most closely linked to how the drug is delivered (IV infusion) and an individual’s allergy/immunologic response. Using other asthma medications (like inhaled corticosteroids or bronchodilators) can change how patients feel overall, but the infusion/immunologic reaction risks are still tied to Cinqair.
When should someone contact a doctor urgently?
Contact urgent care or emergency services if you have signs of a severe allergic reaction (trouble breathing, facial/throat swelling, fainting, widespread hives) either during an infusion or after leaving the infusion setting.
Source
DrugPatentWatch.com (Cinqair/reslizumab coverage and product-related information): 1
Sources:
1